MARKET

PLSE

PLSE

Pulse Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.940
-0.080
-3.96%
After Hours: 1.940 0 0.00% 17:00 06/24 EDT
OPEN
2.000
PREV CLOSE
2.020
HIGH
2.050
LOW
1.860
VOLUME
1.57M
TURNOVER
0
52 WEEK HIGH
29.16
52 WEEK LOW
1.405
MARKET CAP
72.01M
P/E (TTM)
-0.8975
1D
5D
1M
3M
1Y
5Y
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAYWARD, Calif., June 16, 2022--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that the Compensation Committee of its Boa...
Business Wire · 06/16 20:15
Pulse Biosciences's Return On Capital Employed Insights
Pulse Biosciences (NASDAQ:PLSE) brought in sales totaling $444.00 thousand during Q1 according to data provided by Benzinga Pro. However, earnings decreased 12.05%, resulting in a loss of $17.27 million.
Benzinga · 06/16 14:02
Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering
HAYWARD, Calif., June 09, 2022--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today the...
Business Wire · 06/09 20:43
Pulse Biosciences gives results for rights offering
Pulse Biosciences (NASDAQ:PLSE +0.5%) announces that the final subscription price of the rights offering for the units offered is $2.05 per unit, the alternate price, defined as the volume weighted average price for
Seekingalpha · 06/03 14:13
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
HAYWARD, Calif., June 03, 2022--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today pre...
Business Wire · 06/03 12:00
BRIEF-Pulse Biosciences, Inc. Announces Changes To Its Rights Offering
reuters.com · 05/19 14:34
Pulse Biosciences, Inc. Announces Changes to its Rights Offering
HAYWARD, Calif., May 19, 2022--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company commercializing the CellFX® System Powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today two ...
Business Wire · 05/19 12:00
73 Biggest Movers From Yesterday
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.
Benzinga · 05/17 08:49
More
No Data
Learn about the latest financial forecast of PLSE. Analyze the recent business situations of Pulse Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
33.33%Buy
66.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PLSE stock price target is 5.50 with a high estimate of 6.00 and a low estimate of 5.00.
High6.00
Average5.50
Low5.00
Current 1.940
EPS
Actual
Estimate
-0.55-0.41-0.28-0.14
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 70
Institutional Holdings: 4.69M
% Owned: 12.62%
Shares Outstanding: 37.12M
TypeInstitutionsShares
Increased
13
425.90K
New
11
306.25K
Decreased
21
109.61K
Sold Out
5
473.67K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.64%
Healthcare Equipment & Supplies
+2.14%
Key Executives
Non-Executive Chairman/Independent Director
Robert Duggan
President/Chief Executive Officer/Director
Darrin Uecker
Chief Financial Officer/Executive Vice President - Finance/Treasurer/Secretary
Sandra Gardiner
Other
Kevin Danahy
Director
Mitchell Levinson
Independent Director
Manmeet Soni
Independent Director
Shelley Spray
Independent Director
Richard van den Broek
Independent Director
Mahkam Zanganeh
No Data
No Data
About PLSE
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company provides CellFX System, which is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The CellFX System includes a multi-use handpiece and a suite of single-patient use treatment tips ranging from approximately 1.5 square millimeter (mm2) to 10 mm2, enabling treatment of a variety of lesion sizes and depths. The treatment tips wirelessly connect to the CellFX System when plugged into the handpiece, allowing for the use of automated treatment settings based on the treatment tip used. The Company has commercialized its CellFX System into the procedure market as its commercial market. Powered by the Company’s Nano-Pulse Stimulation (NPS) technology, the CellFX System delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue.

Webull offers kinds of Pulse Biosciences Inc stock information, including NASDAQ:PLSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLSE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLSE stock methods without spending real money on the virtual paper trading platform.